Roivant’s Genevant to Share in $2.25 B COVID-19 Vaccine Patent Settlement
Roivant’s Genevant Sciences will share in a $2.25 billion global settlement resolving its COVID-19 vaccine patent litigation with Moderna, including a $950 million payment in Q3 and up to $1.3 billion contingent on appeal outcomes. The deal clears the overhang on Genevant’s IP portfolio and boosts Roivant’s near-term cash flow expectations.
1. Settlement Details
Roivant’s subsidiary Genevant Sciences is party to a global settlement with Moderna totaling $2.25 billion. Moderna will pay $950 million in a lump sum in Q3, with up to $1.3 billion of additional payments conditional on the outcome of a government-contractor immunity appeal.
2. Roivant’s Stake
As Genevant’s parent, Roivant Sciences will recognize its share of the settlement proceeds. This infusion will shore up Roivant’s balance sheet and reduce litigation-related uncertainties surrounding its nanotechnology vaccine platform.
3. Financial Impact
The immediate $950 million payment will bolster Roivant’s cash position, supporting R&D and pipeline advancement. Contingent payments of $1.3 billion, if realized, would represent one of the largest patent settlement inflows in biopharma history.
4. Outlook and Strategy
With the patent dispute resolved, Roivant can redirect resources toward late-stage clinical programs. Management expects the cleared overhang to accelerate partnership discussions and potential commercialization of Genevant’s lipid nanoparticle technologies.